WO2005075492A1 - 5−アミノサリチル酸の配糖体プロドラッグ - Google Patents
5−アミノサリチル酸の配糖体プロドラッグ Download PDFInfo
- Publication number
- WO2005075492A1 WO2005075492A1 PCT/JP2005/001492 JP2005001492W WO2005075492A1 WO 2005075492 A1 WO2005075492 A1 WO 2005075492A1 JP 2005001492 W JP2005001492 W JP 2005001492W WO 2005075492 A1 WO2005075492 A1 WO 2005075492A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- asa
- reaction
- acid
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
Definitions
- the present invention relates to 5-amino-2- (D-galactobilanosyloxy) benzoic acid (hereinafter referred to as “compound [1]”) represented by the following general formula [1] or the following general formula [2] in 5 Ami no 2- (a _D- Galata topics Rano Sil O carboxymethyl) represented benzoic acid (hereinafter, referred to as "compound [2]".) or at a pharmaceutically acceptable salt thereof.
- the present invention also relates to a pharmaceutical composition containing compound [1] or compound [2] or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a compound [1], a compound [2] or a 5-amino-2-(] 3-D darcopyranosyloxy) benzoic acid represented by the following general formula [3] (hereinafter, referred to as “ Compound [3] ”) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 5-Aminosalicylic acid (hereinafter referred to as "5-ASA”! Is a free radical (DPPHL) reduction, hydrogen peroxide scavenger, hypochlorite scavenger, lipid peroxide It has inhibitory action and leukotriene B biosynthesis inhibitory action, so it can be
- UD Ulcerative colitis
- IBD nonspecific inflammatory bowel disease
- CD chronic inflammatory lesions requiring extensive treatment
- DDS drug delivery system
- prodrug conversion of 5-ASA in order to allow 5-AS A to reach the large intestine, which is the site of action
- 5-ASA has been formulated to gradually release 5-ASA from the small intestine to the large intestine by coating 5-ASA with a porous film of ethyl cellulose.
- a formulation (trade name: Pentasa (registered trademark), manufactured by Nisshin Kiyorin Pharmaceutical Co., Ltd.) (for example, see Non-Patent Documents 1 and 2).
- Pentasa registered trademark
- Non-Patent Documents 1 and 2 for example, see Non-Patent Documents 1 and 2
- the plasma unchanged compound concentration was up to lZl4 (maximum) compared to a single oral dose of 5-ASA itself.
- Non-Patent Document 5 a compound in which the amino group of 5-ASA is azozido, salazosulfapyridine (hereinafter, referred to as “SASP”) (trade name: salazopyrin (registered trademark), phasor ( (For example, see Non-Patent Document 3).
- SASP salazosulfapyridine
- phasor a compound in which the amino group of 5-ASA is azozido, salazosulfapyridine
- the compound is present in the colon ⁇ Is metabolized to 5-ASA by intestinal bacteria having azo reductase.
- SASP has been shown to be effective against ulcerative colitis
- SP sulfaviridin
- Another prodrug is a compound obtained by deriving methyl 5-aminosalicylate into a glucose glycoside having high water solubility, such as 5-amino-2-(-D-darcopyranosylo).
- Methyl benzoate and methyl 2-acetoxy 5- ( ⁇ -D "darcopyranosylamino) benzoate are known (for example, see Non-Patent Documents 6 and 7.) The safety of these compounds has been confirmed. The therapeutic effect on ulcerative colitis has been studied!
- a prodrug of a steroid compound which is not 5-ASA but is useful as a therapeutic agent for ulcerative colitis a compound in which dexamethasone or prednisolone is induced into a glycoside such as glucose has been reported (for example, And Patent Document 1).
- the compound is intended to give a specific drug to the large intestine, but when administered to the stomach to rats, only 60% of the dexamethasone glucose derivative and less than 15% of the pred-zolone glucose derivative reach the cecum. T, V, it is reported, V, ru.
- Non-Patent Document 1 Jpn Pharmacology, 104, pp. 447-457 (1994)
- Non-patent document 2 Jpn Pharmacology Journal, 104, pp. 303-311 (1994)
- Non-Patent Document 3 Scandinavian journal of gastroenterology, 23, pp. 107-112 (1988)
- Non-patent document 4 Advanced Drug Delivery Reviews, 7, pp. 149-199 (1991)
- Non-patent document 5 Pharmacology and Therapy, 22 (Suppl. 10), pp. S2467—S2495 (1994)
- Non-patent document 6 Magyar Kemiai Folyoirat, 97 (4), pp. 143-148 (1991)
- Non-Patent Document 7 Archiv der Pharmazie An International Journal Pharmaceutical and Medicinal Chemistry, 332 (9), pp. 321-326 (1999) Disclosure of Invention
- An object of the present invention is to provide 5-ASA, which is useful as a therapeutic agent for ulcerative colitis, in the stomach and upper part of the small intestine!
- An object of the present invention is to provide a safe and long-term therapeutic agent for ulcerative colitis which can be administered.
- the present invention includes, for example, compound [1] or compound [2] or a pharmaceutically acceptable salt thereof.
- the present invention can include a pharmaceutical composition containing the compound [1] or the compound [2] or a pharmaceutically acceptable salt thereof as an active ingredient, and further includes the compound [1], the compound [ 2] or compound [3] (hereinafter, referred to as “the compound of the present invention” for convenience) or a pharmaceutically acceptable salt thereof as an active ingredient for treating ulcerative colitis.
- the compound of the present invention is metabolized to 5-ASA by the intestinal flora in the large intestine, systemic side effects can be reduced, and a relatively large dose of the compound of the present invention can be used. Long V allows prescribing over time.
- “Ulcerative colitis” is unexplained erosive nonspecific inflammation of the large intestine that mainly affects the mucous membrane and often forms erosions and ulcers. [0010] Hereinafter, the present invention! /, Elaborate.
- the compound of the present invention can be produced from a known compound or an easily prepared intermediate, for example, according to the following method.
- the reaction is generally carried out after protecting the starting material with an appropriate protecting group by a known method in advance. After the reaction, the protecting group can be removed by a known method.
- R 1 is a linear or branched alkyl having 16 carbon atoms
- R 2 is D-dalcopyranosyl or D-galactopyranosyl (each hydroxyl group of R 2 is acetyl, etc.)
- X represents a halogen such as fluorine, chlorine, bromine or iodine.
- This reaction is a known esterification reaction of compound [4], and can be carried out by a known method (see Non-Patent Document 7).
- the appropriate reaction temperature is 20-200 ° C.
- the reaction solvent generally varies depending on the type of the carboxylic acid ester to be produced, and examples thereof include alcohols such as methanol and ethanol.
- Examples of the acid include inorganic acids such as hydrochloric acid and sulfuric acid.
- the reaction time varies depending on the type of raw materials used and the reaction temperature. Usually, 1 hour to 72 hours is appropriate. [0013] Step 2
- This reaction is a condensation reaction between compound [5] and a compound in which the anomeric position of glucose or galactose is halogenated, and can be carried out by a method known per se (see Non-Patent Document 7).
- This reaction proceeds by steric inversion in the presence of a catalyst.
- the catalyst for this reaction include silver oxide (1), mercury oxide (II), and AgOCOR 3 (R 3 represents a linear or branched alkyl having 16 to 16 carbon atoms).
- the reaction solvent is not particularly limited as long as it does not generally participate in the reaction, and examples thereof include quinoline.
- the reaction temperature is suitably from 0 to 100 ° C.
- the reaction time varies depending on the type of the starting material used, the reaction temperature, and the like. Usually, 117 hours is appropriate. Further, if necessary, the protecting group for each hydroxyl group of R 2 of the produced compound [6] may be eliminated by a known method.
- compound [9] which is a starting compound, may be a commercially available compound.
- compound [9] can also be produced by the following method.
- This reaction is a reaction for halogenating the anomeric position of a sugar such as glucose or galactose, and can be carried out by a method known per se.
- a hydrogen bromide-acetic acid solution, phosphorus oxybromide, phosphorus oxychloride and the like are generally used, and the reaction solvent is not particularly limited as long as it does not generally participate in the reaction. Examples thereof include halogen solvents such as methylene chloride, chloroform, 1,2-dichloroethane, and the like.
- the reaction temperature is suitably from 0 to 100 ° C.
- the reaction time varies depending on the type of the starting material used and the reaction temperature, but usually, 1 hour to 72 hours is appropriate.
- This reaction is a reaction for hydrogenating compound [6], and can be performed by a method known per se (see Non-Patent Document 7).
- This reaction can be carried out, for example, in the presence of a metal catalyst in a suitable solvent, generally under a hydrogen pressure of 110 atm, at 0-100 ° C.
- a metal catalyst palladium carbon, noradium black, platinum dioxide, platinum carbon, and the like are generally used, and the reaction solvent is not particularly limited as long as it does not participate in the reaction.
- Ethers such as hydrofuran, 1,4-dioxane and 1,2-dimethoxyethane, alcohols such as methanol and ethanol, amides such as N, N-dimethylformamide and N, N-dimethylacetamide, benzene, toluene, Examples thereof include hydrocarbons such as xylene, and a mixed solvent thereof.
- the reaction time varies depending on the type of the starting material used and the reaction temperature, but usually, an appropriate time is 1 to 48 hours.
- the protecting group for each hydroxyl group of R 2 of the prepared conjugate [7] may be eliminated by a known method.
- This reaction is a reaction for hydrolyzing the carboxylic acid ester of the compound [7], and can be performed by a method known per se.
- the reaction temperature is suitably 0-100 ° C.
- the reaction solvent is not particularly limited as long as it does not generally participate in the reaction, and examples thereof include alcohols such as methanol and ethanol.
- Examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide.
- the reaction time varies depending on the type of the starting materials used and the reaction temperature, but usually, an appropriate time is 117 hours.
- R 1 R 2 has the same meaning as described above.
- X 1 represents halogen such as fluorine, chlorine, bromine and iodine.
- This reaction is a known esterification reaction of compound [10], and can be carried out by a known method (see Non-Patent Document 7).
- the appropriate reaction temperature is 20-200 ° C.
- the reaction solvent generally varies depending on the type of the carboxylic acid ester to be produced, and examples thereof include alcohols such as methanol and ethanol.
- Examples of the acid include inorganic acids such as hydrochloric acid and sulfuric acid.
- the reaction time varies depending on the type of raw material used and the reaction temperature. Usually, an appropriate time is 117 hours.
- This reaction is a condensation reaction between compound [11] and glucose or galactose derivative [12], and can be carried out by a method known per se.
- a base can be exemplified.
- this reaction since the stereo at the anomeric position cannot be controlled, it is necessary to separate and purify into a single diastereomer by silica gel chromatography or the like. By this separation operation, both compounds (a-form and 3-form) can be obtained in the stereo configuration at the anomeric position.
- Examples of the base used in this reaction include, for example, 1,5-diazabicyclo [4.3.0] -5-nonene, 1,4-diazabicyclo [2.2.2] octane, 1,8-diazabicyclo [5 . 4.0] —7-indene.
- the reaction solvent is not particularly limited as long as it does not generally participate in the reaction, and examples thereof include acetonitrile and dimethyl sulfoxide.
- the reaction temperature is suitably 0-100 ° C.
- the reaction time varies depending on the type of the starting material used, the reaction temperature, and the like, but usually, 117 hours is appropriate. Further, if necessary, the protecting group for each hydroxyl group of R 2 of the produced compound [6] may be eliminated by a known method.
- the thus prepared conjugate of the present invention can be obtained by a means known per se, for example, concentration, liquid conversion, phase transfer, solvent extraction, crystallization, recrystallization, fractionation, or chromatography. It can be separated and refined.
- the compound of the present invention can be used as a medicament as it is.
- a pharmaceutically acceptable salt can be formed by a known method.
- salts for example, hydrogen chloride, sulfuric acid, nitrate Salts of inorganic acids such as acid, phosphoric acid, hydrofluoric acid, and hydrobromic acid, acetic acid, tartaric acid, lactic acid, formic acid, fumanoleic acid, maleic acid, succinic acid, methanesulfonic acid, ethanesnolephonic acid, benzenesulfonic acid And salts of organic acids such as toluenesulfonic acid, naphthalenesulfonic acid and camphorsulfonic acid, and salts of alkali metals or alkaline earth metals such as sodium, potassium and calcium.
- inorganic acids such as acid, phosphoric acid, hydrofluoric acid, and hydrobromic acid
- acetic acid tartaric acid
- lactic acid formic acid, fumanoleic acid, maleic acid, succinic acid, methanesulfonic acid, ethanesnolephonic acid,
- Preferred salts include the hydrochloride salt.
- the hydrochloride of the compound of the present invention is prepared by treating the compound of the present invention with an alcohol solution of hydrogen chloride or getyl ether solution, and collecting the precipitated crystals by filtration, or concentrating the solution if no crystals are precipitated. Can be obtained by precipitating and then collecting by filtration.
- the compound of the present invention has almost no entry into plasma, V !, and it is not an existing 5-ASA-related drug! / ⁇ Achieve the widespread active ingredient, 5-—ASA, with excellent characteristics and efficiently through oral administration to the entire colon, including the cecum, proximal colon, distal colon, and the Z or rectum, which are disease sites. Can be. Therefore, the compound of the present invention is useful as a safe and long-term therapeutic agent for ulcerative colitis. Particularly, the effect of the compound [1] is remarkable.
- the compound of the present invention significantly inhibited the damage score and wet weight of the large intestine as a result of examining the efficacy of compound [1] in a rat model of trinitrobenzenesulfonic acid (TNBS) -induced colitis. And is an excellent therapeutic agent for ulcerative colitis.
- TNBS trinitrobenzenesulfonic acid
- the compound of the present invention When the compound of the present invention is administered as a medicament, the compound of the present invention or a pharmaceutically acceptable salt thereof may be used as it is or in a pharmaceutically acceptable nontoxic and inert carrier, for example, in an amount of 0.1% — It is administered to mammals including humans as a pharmaceutical composition containing 99.5%, preferably 0.5% -90%.
- Pharmaceutically acceptable carriers include one or more solid, semi-solid or liquid diluents, fillers and other formulation aids.
- the pharmaceutical compositions are administered in dosage unit form.
- the pharmaceutical composition can be administered orally or parenterally (eg, rectally). Needless to say, it is administered in a dosage form suitable for these administration methods.
- oral administration is preferred.
- the dose of the compound of the present invention or a pharmaceutically acceptable salt thereof is preferably adjusted in consideration of the patient's condition such as age, body weight, nature of the disease, degree, etc., and the administration route.
- the appropriate amount of the active ingredient of the compound of the present invention or a pharmaceutically acceptable salt thereof for an adult is, in the case of oral administration, in the range of lOmg 10 gZ adult per day, preferably in the range of lg-4 gZ adult. . In some cases, lower doses may be sufficient and conversely, higher doses may be required. Usually, it can be administered once or several times a day.
- Oral administration can be carried out in solid or liquid dosage units, for example, powders, powders, tablets, dragees, capsules, granules, solutions, syrups, suppositories and other dosage forms.
- Powders are prepared by converting the compound of the present invention or a pharmaceutically acceptable salt thereof into an appropriate powder.
- Capsules are manufactured by first filling powdered powders, powders, or granules as described in the section on powders as described above into a capsule shell such as a gelatin capsule. Is done. Lubricants and fluidizers such as colloidal silica, talc, magnesium stearate, calcium stearate, and solid polyethylene glycol are mixed with the powdered state, and then the filling operation is performed. You can also.
- Disintegrants and solubilizers such as carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium, sodium carboxymethyl starch, calcium carbonate, sodium carbonate, phosphoric anhydride
- the addition of calcium hydrogen can improve the efficacy of the medicament when the capsule is ingested.
- Tablets are made by adding an excipient, forming a powder mixture, granulating or slugging, then adding a disintegrant or lubricant and compressing.
- a powder mixture Mixes appropriately powdered substances with the above-mentioned diluents and bases and, if necessary, binders (eg sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, gelatin, polybutylpyrrolidone, polybutyl alcohol), Dissolution retardants (eg, paraffin), resorbents (eg, quaternary salts) and adsorbents (eg, bentonite, kaolin, dicalcium phosphate) can be used in combination.
- binders eg sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, gelatin, polybutylpyrrolidone, polybutyl alcohol
- Dissolution retardants eg, paraffin
- resorbents eg, quaternary
- the powder mixture can be first moistened with a binder such as syrup, starch paste, gum arabic, a cellulose solution or a polymer solution, stirred and mixed, and dried and ground to form granules.
- a binder such as syrup, starch paste, gum arabic, a cellulose solution or a polymer solution
- stearic acid, stearic acid salt, talc, mineral oil and the like as a lubricant, the granules thus produced can be prevented from adhering to each other.
- the mixture thus lubricated is tableted with the following V:
- the uncoated tablets thus produced can be coated with a film or coated with sugar.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be directly tableted after mixing with a fluid inert carrier without going through the granulating and slagging steps as described above. You may. Transparent or translucent protective coatings consisting of shellac sealing coatings, coatings of sugar or polymeric materials, and polishing coatings made of wax can also be used. Other oral dosage forms such as solutions, syrups and elixirs can also be presented in dosage unit form so that a given quantity contains a fixed amount of the drug. Syrups are produced by dissolving the compound of the present invention or a pharmaceutically acceptable salt thereof in a suitable flavor aqueous solution, and elixirs are produced by using a non-toxic alcoholic carrier.
- dosage unit formulations for oral administration may be microencapsulated.
- the formulation can also provide a prolonged action or sustained release by coating or embedding in a polymer 'wax or the like.
- Suppositories and the like can be used for parenteral administration.
- the compound of the present invention or a pharmaceutically acceptable salt thereof is low-melting, water-soluble or insoluble solid, for example, polyethylene glycol, cocoa butter, semi-synthetic fat (for example, Vitebsol Z (registered trademark)).
- a suppository prepared by dissolving or suspending in esters for example, myristyl palmitate
- esters for example, myristyl palmitate
- FIG. 1 shows changes in the concentration of 5-ASA in plasma.
- the vertical axis represents the concentration (ngZml) of 5-ASA present in rat plasma, and the horizontal axis represents time (hour).
- Black circles indicate the case where compound [1] was administered, white diamonds indicate the case where compound [2] was administered, white triangles indicate the case where compound [3] was administered, and white circles indicate the case where Pentasa (registered trademark) was administered 5—Represents the transition of the concentration of ASA.
- FIG. 2 shows changes in the amount of 5-ASA in cecal contents.
- the vertical axis represents 5-83 times (% of dose) present in rat cecal contents, and the horizontal axis represents time (hours).
- the black circles indicate the change in the amount of 5-AS A when the compound [1] was administered
- the white circles indicate the changes in the amount of 5-AS A when Pentasa (registered trademark) was administered
- the black triangles indicate the changes in the amount when 5-AS A was administered.
- FIG. 3 shows changes in the amount of 5-ASA in the contents of the proximal colon.
- the vertical axis represents 5-83 times (% of dose) present in rat proximal colon contents, and the horizontal axis represents time (hours).
- the solid circles indicate the changes in the amount of 5-AS A when the compound [1] was administered, the open circles indicate the changes in the amount of 5-ASA when administered Pentasa (registered trademark), and the solid triangles indicate the changes in the amount when 5-ASA was administered.
- FIG. 4 shows changes in the amount of 5-ASA in distal colon contents.
- the vertical axis represents 5-83 times (% of dose) present in rat distal colon contents, and the horizontal axis represents time (hours).
- the black circles indicate the changes in the amount of 5-AS A when the compound [1] was administered
- the white circles indicate the changes in the amount of 5-ASA when administered Pentasa (registered trademark)
- the black triangles indicate the changes in the amount when 5-AS A was administered.
- FIG. 5 shows changes in the amount of 5-ASA in rectal contents.
- the vertical axis represents 5-83 times (% of dose) present in rat rectal contents, and the horizontal axis represents time (hours).
- the solid circles indicate the changes in the amount of 5-AS A when the compound [1] was administered, the open circles indicate the changes in the amount of 5-AS A when Pentasa (registered trademark) was administered, and the solid triangles indicate the changes in the amount when 5-AS A was administered.
- FIG. 6 shows changes in the concentration of 5-ASA in colon tissue.
- the vertical axis represents the concentration ( ⁇ g / g) of 5-ASA present in rat colon lg, and the horizontal axis represents time (hour).
- Open diamonds indicate 5- ⁇ A when compound [2] was administered, and open circles indicate 5-A when compound Pentasa (registered trademark) was administered.
- Each represents the transition of SA concentration.
- FIG. 7 shows changes in the concentration of 5-ASA in rectal tissue.
- the vertical axis represents the concentration ( ⁇ g / g) of 5-ASA present in rat rectum lg, and the horizontal axis represents time (hours).
- the open diamonds indicate the changes in the concentration of 5-ASA when the compound [2] was administered, and the open circles indicate the changes in the concentration of 5-ASA when administered Pentasa (registered trademark).
- FIG. 8 shows the therapeutic effect of Pentasa (registered trademark) and i-conjugated product [1] on TNBS-induced colitis in rats by damage score.
- the vertical axis represents the damage score, and the horizontal axis represents the dose (mgZkg / dose) of each test drug.
- FIG. 9 shows the effect of Pentasa (registered trademark) and Yidani-drug [1] on TNBS-induced colitis in rats on the increase in wet tissue weight associated with the onset of colitis.
- the vertical axis shows colon wet weight (g).
- the horizontal axis represents the dose of each test drug (mgZkgZ times).
- Step 2 1 2 ' L 3' ._4 ⁇ 6 '-tetra-O-acetyl-a-D-galactopyranosyl bromide
- Step 2-2 Methyl 5- (2-, 2,3,4'.6,1-tetra-O-acetinol-D-galactopyranosyloxy) benzoate
- Methyl 5-benzo obtained in step 2-2 2- (2,3 ', 4', 6'-tetra-O-acetyl- / 3-D-galactovilanosyloxy) benzoate 10.55 g of methanol The solution was stirred at 60 ° C. and sodium methoxide was added. After stirring for 30 minutes, the reaction mixture was neutralized with Amberlite IRC-50 (5.0 g). After filtration, the organic layer was concentrated to obtain 4.90 g of methyl 5-nitro-2-(/ 3-D-galatato pyranosyloxy) benzoate.
- methanol 100 ml
- hydrogen 1 10% palladium on carbon (0.49 g)
- the catalytic reduction reaction was performed at atmospheric pressure and room temperature. Twenty hours later, the reaction solution was filtered to remove the catalyst, and the organic layer was concentrated to obtain 4.18 g of methyl 5-amino-2 (D-galactobilanosyloxy) benzoate.
- Step 4 5 Amino-2- ( ⁇ D-galactobilanosyloxy) benzoic acid
- Methyl 5-amino-2- ( ⁇ -D-galatatopyranosyloxy) benzoate obtained in step 2-4 4.
- a 1N aqueous sodium hydroxide solution (12 ml). .7 ml
- the reaction solution was directly concentrated under reduced pressure, and the residue was diluted with distilled water. Thereafter, the mixture was neutralized with 2N hydrochloric acid (6.4 ml). The mixture was concentrated to obtain 3.41 g of the target compound.
- Step 3-1 Amino-2- (2'.3'.4'.6'-tetra-O-acetyl-a-D_galactopyranosyloxy) benzoate methyl acid
- Methyl 5- (2-, 2-, 2,3,4,6'-tetra-O-acetyl-a-D-galactobilanosyloxy) benzoate obtained in step 2-1 7.00 g of methanol (210 ml) 10% palladium on carbon (0.70 g) was added to the solution, and a catalytic reduction reaction was performed at room temperature and 1 atm of hydrogen. After 18 hours, the reaction solution was filtered to remove the catalyst, and the organic layer was concentrated.
- Step 2 5-—Trow 2- (2′.3 ′, 4′.6, -tetra-O-acetyl- ⁇ D-Darcopyranosiloxy) methyl benzoate
- Step 3-1 5-Amino-2- (2'.3, .4'.6-, tetra-O-acetyl- ⁇ D-Darcopyrano siloxy) methyl benzoate
- 5-ASA 7-week-old SD male rats were intravenously administered with 5-ASA as a test drug, and compound [1], conjugated compound [2], compound [3] and Pentasa (registered trademark) were added to 5-ASA. Oral administration of 50 mgZ kg was calculated and the 5-ASA concentration in plasma was measured by high performance liquid chromatography (HPLC). Pentasa (registered trademark) was obtained by pulverizing Pentasa (registered trademark) tablets into granules.
- the amount of 5-ASA in each part of the large intestine was highest when compound [1] was administered (see FIGS. 2, 3, 4, and 5).
- compound [2] and Pentasa were orally administered as test drugs in an amount of 50 mg Zkg in terms of 5-ASA, and the colon and rectum were homogenized.
- 5-ASA concentration in colon tissue and rectum tissue was measured by chromatography (HPLC).
- Pentasa was obtained by pulverizing Pentasa (registered trademark) tablets into granules.
- Test Example 1 compound [1] and compound [2] were hydrolyzed in the stomach and small intestine. It does not produce 5-AS A in the stomach and upper small intestine, and has a low absorption rate from the digestive tract.
- Test Example 2 revealed that compound [1] and compound [2] reached the diseased large intestine and were metabolized to 5-ASA by intestinal bacteria.
- compound [1] was detected in high concentrations of 5-ASA, which is effective in treating ulcerative colitis, in various parts of the large intestine
- Colitis was induced by administering an aqueous solution (30 mg ZO., 25 ml Z rat) into the large intestine 8 cm from the anus using an oral administration probe. Three days after TNBS administration, the large intestine was excised, the wet weight of the large intestine was measured 8 cm from the anus, and the degree of colitis was scored according to the method of Wallace et al. (Gastroenterology, 96, p. 29-36 (1989)). did.
- Pentasa (registered trademark) was administered at a dose of 30,100 mgZkg, and compound [1] at a dose of 61.8, 205.9 mg / kg (equivalent to 30,100 mgZkg in terms of ASA) twice daily (TNBS administration). It was given orally 4 hours before TNBS administration. Pentasa (registered trademark) was obtained by pulverizing Pentasa (registered trademark) tablets into granules.
- the compound of the present invention can efficiently cause 5-ASA, which is effective in treating ulcerative colitis, to reach the large intestine, which is the site of action, and does not transfer 5-ASA to plasma. / Features That is, systemic side effects can be reduced, and the dose can be increased until the maximum therapeutic effect is obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05709613A EP1712555A4 (en) | 2004-02-03 | 2005-02-02 | 5-AMINOSALICYLATE GLYCOSIDE-CONTAINING PRODRUG |
US10/597,695 US20070173461A1 (en) | 2004-02-03 | 2005-02-02 | Glycoside prodrug of 5- aminosalicylic acid |
CA002554091A CA2554091A1 (en) | 2004-02-03 | 2005-02-02 | Prodrug comprising 5-aminosalicylate glycoside |
JP2005517698A JPWO2005075492A1 (ja) | 2004-02-03 | 2005-02-02 | 5−アミノサリチル酸の配糖体プロドラッグ |
BRPI0507384-7A BRPI0507384A (pt) | 2004-02-03 | 2005-02-02 | pró-droga glicosìdica de ácido 5-aminossalicìlico |
AU2005210299A AU2005210299A1 (en) | 2004-02-03 | 2005-02-02 | Prodrug comprising 5-aminosalicylate glycoside |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004026916 | 2004-02-03 | ||
JP2004-026916 | 2004-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005075492A1 true WO2005075492A1 (ja) | 2005-08-18 |
Family
ID=34835875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001492 WO2005075492A1 (ja) | 2004-02-03 | 2005-02-02 | 5−アミノサリチル酸の配糖体プロドラッグ |
Country Status (10)
Country | Link |
---|---|
US (1) | US20070173461A1 (ja) |
EP (1) | EP1712555A4 (ja) |
JP (1) | JPWO2005075492A1 (ja) |
KR (1) | KR20060129038A (ja) |
CN (1) | CN1914220A (ja) |
AU (1) | AU2005210299A1 (ja) |
BR (1) | BRPI0507384A (ja) |
CA (1) | CA2554091A1 (ja) |
RU (1) | RU2341529C2 (ja) |
WO (1) | WO2005075492A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103254257A (zh) * | 2013-04-18 | 2013-08-21 | 山西医科大学 | 一种4-氨基水杨酸糖苷类衍生物及其制备方法 |
CN101863934B (zh) * | 2009-04-20 | 2014-07-23 | 中国医学科学院药物研究所 | 水杨酸甲酯糖苷类化合物、其合成方法与用途 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
GB2493712B (en) | 2011-08-12 | 2014-07-02 | Gene Onyx Ltd | Insulin pump |
KR20200011972A (ko) * | 2017-06-05 | 2020-02-04 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 멀티바이오틱제 및 이를 사용하는 방법 |
WO2019236772A1 (en) * | 2018-06-05 | 2019-12-12 | Flagship Pioneering Innovations V, Inc. | Acylated active agents and methods of their use for the treatment of autoimmune disorders |
GB201904758D0 (en) * | 2019-04-04 | 2019-05-22 | Univ British Columbia | Xyloglucan-containing prodrugs and methods of manufacture and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6069061A (ja) * | 1983-07-01 | 1985-04-19 | ヘニング ベルリン ゲーエムベーハー ヘミー ウント フアルマベルケ | 5―アミノサリチル酸―o―サルフェートの塩 |
JPS60501105A (ja) * | 1983-04-14 | 1985-07-18 | ザ ・レ−ゲンツ・オブ・ザ・ユニバ−シティ・オブ・カリフォルニヤ | 結腸特異性の薬剤付与系 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5924966B2 (ja) * | 1978-12-29 | 1984-06-13 | 呉羽化学工業株式会社 | アミノ安息香酸誘導体又はその医薬上許容される塩を有効成分とする抗炎症剤 |
-
2005
- 2005-02-02 KR KR1020067017624A patent/KR20060129038A/ko not_active Application Discontinuation
- 2005-02-02 JP JP2005517698A patent/JPWO2005075492A1/ja active Pending
- 2005-02-02 BR BRPI0507384-7A patent/BRPI0507384A/pt not_active IP Right Cessation
- 2005-02-02 US US10/597,695 patent/US20070173461A1/en not_active Abandoned
- 2005-02-02 WO PCT/JP2005/001492 patent/WO2005075492A1/ja active Application Filing
- 2005-02-02 RU RU2006131594/04A patent/RU2341529C2/ru not_active IP Right Cessation
- 2005-02-02 AU AU2005210299A patent/AU2005210299A1/en not_active Abandoned
- 2005-02-02 CN CNA2005800035809A patent/CN1914220A/zh active Pending
- 2005-02-02 EP EP05709613A patent/EP1712555A4/en not_active Withdrawn
- 2005-02-02 CA CA002554091A patent/CA2554091A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60501105A (ja) * | 1983-04-14 | 1985-07-18 | ザ ・レ−ゲンツ・オブ・ザ・ユニバ−シティ・オブ・カリフォルニヤ | 結腸特異性の薬剤付与系 |
JPS6069061A (ja) * | 1983-07-01 | 1985-04-19 | ヘニング ベルリン ゲーエムベーハー ヘミー ウント フアルマベルケ | 5―アミノサリチル酸―o―サルフェートの塩 |
Non-Patent Citations (3)
Title |
---|
GOTO M. ET AL: "Anti-inflammatory effects of 5 animo-salicyclic acid conjugates with chenodeoxycholic acid and urs odeoxycholic acid on carrageenan-induced colitis in guinea-pigs,", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 53, 2001, pages 1711 - 1720, XP002989504 * |
See also references of EP1712555A4 * |
SZTARICSKAI F. ET AL: "Antiulcer effect of the N and O- B -D- glucopyranosides of 5-aminosalicylic acid.", ARCH.PHARM. PHARM. MED.CHEM., vol. 332, no. 9, 1999, pages 321 - 326, XP002989503 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863934B (zh) * | 2009-04-20 | 2014-07-23 | 中国医学科学院药物研究所 | 水杨酸甲酯糖苷类化合物、其合成方法与用途 |
CN103254257A (zh) * | 2013-04-18 | 2013-08-21 | 山西医科大学 | 一种4-氨基水杨酸糖苷类衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005075492A1 (ja) | 2007-10-11 |
EP1712555A1 (en) | 2006-10-18 |
RU2006131594A (ru) | 2008-03-10 |
AU2005210299A1 (en) | 2005-08-18 |
EP1712555A4 (en) | 2008-04-02 |
US20070173461A1 (en) | 2007-07-26 |
CN1914220A (zh) | 2007-02-14 |
BRPI0507384A (pt) | 2007-07-10 |
KR20060129038A (ko) | 2006-12-14 |
CA2554091A1 (en) | 2005-08-18 |
RU2341529C2 (ru) | 2008-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6737838B2 (ja) | Mek阻害剤の調製およびmek阻害剤を含む製剤 | |
JP2811353B2 (ja) | 炎症性腸疾患予防・治療剤 | |
WO2005075492A1 (ja) | 5−アミノサリチル酸の配糖体プロドラッグ | |
JPH027957B2 (ja) | ||
JP2879344B2 (ja) | 3―ホルミルアミノ―7―メチルスルホニルアミノ―6―フェノキシ―4h―1―ベンゾピラン―4―オンまたはその塩を含有する抗炎症製剤 | |
US20090136570A1 (en) | Taste-Masked Tablets and Granules | |
WO2009015541A1 (fr) | Antibiotiques à base de diesters de polyènes | |
EP2629778B1 (en) | Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome | |
WO2001056568A1 (fr) | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine | |
EP0817631A2 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
ES2358564T3 (es) | Derivados de carbonilamino útiles para el tratamiento de una enfermedad inflamatoria intestinal. | |
WO2011085606A1 (zh) | 用于抗感染的普卢利沙星的光学活性化合物和制备方法 | |
JPS60501561A (ja) | アゾ−ビス−サリチル酸およびその塩、該酸および該塩の薬学的処方および使用、並びに該酸の製造 | |
EP4054613A1 (en) | Gut-protective compositions comprising boswellic acid | |
CA1303508C (en) | Use of dihydro benzopyran derivatives | |
MXPA06008747A (en) | Prodrug comprising 5-aminosalicylate glycoside | |
ITMI980253A1 (it) | Sali micronizzati di nimesulide | |
JP2659126B2 (ja) | 抗潰瘍剤 | |
WO2024061213A1 (zh) | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 | |
JPH0558885A (ja) | 抗潰瘍剤 | |
TW200424205A (en) | Pyrrolopyridazine derivatives acid addition salts | |
JPH02149522A (ja) | 胃炎治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517698 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554091 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005210299 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580003580.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/008747 Country of ref document: MX Ref document number: 2833/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007173461 Country of ref document: US Ref document number: 10597695 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005709613 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005210299 Country of ref document: AU Date of ref document: 20050202 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005210299 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067017624 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006131594 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005709613 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067017624 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0507384 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10597695 Country of ref document: US |